370 related articles for article (PubMed ID: 24640604)
1. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
4. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
7. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
Srinivas NR
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
[TBL] [Abstract][Full Text] [Related]
8. A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol.
Borlak J; Hermann R; Erb K; Thum T
Metabolism; 2003 Nov; 52(11):1439-43. PubMed ID: 14624403
[TBL] [Abstract][Full Text] [Related]
9. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
[TBL] [Abstract][Full Text] [Related]
10. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
12. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.
Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J
Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
14. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients.
Dong H; Lu SJ; Zhang R; Liu DD; Zhang YZ; Song CY
Eur J Clin Pharmacol; 2015 Jun; 71(6):681-686. PubMed ID: 25948472
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
16. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers.
de Moraes NV; Lauretti GR; Lanchote VL
J Pharm Pharmacol; 2014 Sep; 66(9):1222-30. PubMed ID: 24717054
[TBL] [Abstract][Full Text] [Related]
17. Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption.
Stamer UM; Musshoff F; Stüber F; Brockmöller J; Steffens M; Tzvetkov MV
Pain; 2016 Nov; 157(11):2467-2475. PubMed ID: 27541716
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of tramadol and
Lee J; Yoo HD; Bae JW; Lee S; Shin KH
Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
[No Abstract] [Full Text] [Related]
19. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
20. Miotic action of tramadol is determined by CYP2D6 genotype.
Slanar O; Nobilis M; Kvetina J; Mikoviny R; Zima T; Idle JR; Perlík F
Physiol Res; 2007; 56(1):129-136. PubMed ID: 16497087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]